Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer

17 Oct 2020

Abstract excerpt

Since metastatic colorectal cancer (CRC) is a leading cause of cancer-related death, therapeutic approaches overcoming primary and acquired therapy resistance are an urgent medical need. In this study, the efficacy and toxicity of high-affinity inhibitors targeting antiapoptotic BCL-2 proteins (BCL-2, BCL-XL, and MCL-1) were evaluated. By RNA sequencing analysis of a pan-cancer cohort comprising >1500 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Cancer therapeutics and mechanisms
Share to Cell death mechanisms and regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33070156
DOI: 10.1038/s41419-020-03092-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancerPMID 33070156Read ↗

Bcl-xL is an oncogenic driver in colorectal cancer.Semantic proximity Read ↗

A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers.Semantic proximity Read ↗

BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancerSemantic proximity Read ↗

CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers.Semantic proximity Read ↗

Bcl‐xL as prognostic marker and potential therapeutic target in cholangiocarcinomaSemantic proximity Read ↗

Toward Targeting Antiapoptotic MCL-1 for Cancer TherapySemantic proximity Read ↗

Attacking cancer's Achilles heel: antagonism of anti‐apoptotic <scp>BCL</scp>‐2 family membersSemantic proximity Read ↗

Bcl-xL is a key mediator of apoptosis following KRAS <sup>G12C</sup> inhibition in <i>KRAS</i> <sup> <i>G12C</i> </sup> mutant colorectal cancerSemantic proximity Read ↗

Discovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancerSemantic proximity Read ↗

Modulating the Bcl-2 Family of Apoptosis Suppressors for Potential Therapeutic Benefit in CancerSemantic proximity Read ↗

Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.Semantic proximity Read ↗

MCL1 nuclear translocation induces chemoresistance in colorectal carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.